Table 4 Univariate and multivariate cox regression models of tuberculosis in SpA

Age (years)

0.93 (0.91–0.95)

< 0.001

Male sex

2.29 (1.02–5.15)

0.05

Smoking

1.74 (0.95–3.19)

0.07

Alcohol use

2.29 (1.06–4.94)

0.04

History of psoriasis

0.51 (0.21–1.20)

0.12

History of IBD

1.43 (0.20–10.37)

0.73

DM

0.72 (0.26–2.03)

0.54

Past history of TB

6.88 (3.28–14.41)

< 0.001

CKD

0.89 (0.32–2.51)

0.83

CLD

4.48 (2.07–9.72)

< 0.001

Malignancy

2.07 (0.74–5.80)

0.17

CHD

0.88 (0.31–2.47)

0.81

Other immunosuppressive states

0.95 (0.13–6.89)

0.96

History of CVA

1.46 (0.52–4.09)

0.48

Glucocorticoid therapy > 6 months

2.21 (0.93–5.25)

0.03

Sulfasalazine

0.63 (0.34–1.16)

0.14

Methotrexate

0.57 (0.27–1.19)

0.13

Lefluonomide

0.05 (0.00–13.72)

0.29

Infliximab

5.08 (2.49–10.34)

< 0.001

Etanercept

0.57 (0.14–2.36)

0.44

Adalimumab

1.83 (0.72–4.67)

0.21

Certolizumab

0.05 (0.00–32,169)

0.66

Golimumab

0.05 (0.00–13.94)

0.29

Secukinumab

0.05 (0.00–282.43)

0.49

Ustekinumab

0.05 (0.00–657,547)

0.72